July 27, 2017: Primetime Life Science, LLC’s initiated a collaboration with NCI for Development of ROS-Generating Molecules for Localized Delivery of Therapeutics.
May 5, 2017: Primetime Life Science, LLC’s entered in a sponsored research agreement with Universality of Maryland, Baltimore to evaluate Primetime’s mutual prodrugs for anticancer activities.
September 30, 2016: Primetime awarded with a service contract by a Maryland Pharmaceutical company to develop prodrug its leading drug.
April 26, 2016: Primetime Life Science, LLC’s CEO & President, Janak Padia, Ph.D. to present the company's mutual prodrug platform technology at BIT's 1st Annual International Congress of Genetics-2016.
April 06, 2016: Primetime Life Sciences enters in a CRADA with the VA Medical Center to test mutual drugs for their effect on stem cell growth and to study their underlying mechanisms.
November 24, 2015: Primetime Life Sciences collaborates with NIH to test novel mutual drugs for the treatment of thyroid cancers.
November 05, 2015: Primetime Life Sciences, LLC enters into a consulting agreement with the University of Maryland - Institute for Bioscience and Biotechnology Research (IBBR) to provide services to translate its research projects for commercialization
November 02, 2015: Primetime Life Science, LLC’s CEO & President, Janak Padia, Ph.D. to discuss the importance of early ADME/Tox in drug discovery at the Pharma Middle East conference in Dubai, UAE.
October 30, 2015: Primetime Life Sciences, LLC was awarded a sub-award from the National Institutes of Health via the University of Maryland to discover and develop Fumagillin Derivatives as Novel Antigiardiasis and Antiamebiasis Drugs.
September 25, 2015: Primetime Life Sciences signs a master service agreement with Noble Life Sciences to share Noble’s office and lab facilities.
September 11, 2015: Investigators from Primetime Life Sciences, NIDDK/NIH, and the Saint Louis University School of Medicine coauthored article “Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain”. PMID: 26111639 PMCID: DOI: 10.1007/s11302-015-9459-2
August 15, 2015: Janak Padia, Ph.D. of Primetime Life Sciences coauthored an article in Journal of Medicinal Chemistry, “Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors”; PMID: 26182238 DOI: 10.1021/acs.jmedchem.5b00460
August 11, 2015: Janak Padia, Ph.D. of Primetime Life Science, LLC to present the company technologies at the International Conference and Expo on Drug Discovery & Designing in Frankfurt, Germany.
February 20, 2014: Primetime Life Sciences, Georgetown University, and Northwestern University published a book chapter titled “Small Molecule Inhibitor Discovery for Dengue Virus Protease Using High-Throughput Screening” Dengue: Methods and Protocols, Humana Press: Volume 1138 of the series Methods in Molecular Biology pp 331-344. PMID: 24696346 DOI: 10.1007/978-1-4939-0348-1_20
May 13, 2013: Primetime Life Sciences, LLC signed an agreement with Cary Pharmaceuticals to provide consulting services for regulatory approval of the medical devices.
February 13, 2013: Primetime Life Sciences, LLC, a Germantown, MD-based pharmaceutical R&D company, entered an agreement to provide medicinal chemistry services to help drive ConverGene, LLC’s ongoing research activities.